460
Participants
Start Date
September 30, 2013
Primary Completion Date
January 11, 2018
Study Completion Date
January 11, 2018
Secukinumab
"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
Placebo
Placebo
Novartis Investigative Site, Manila
Novartis Investigative Site, Manila
Novartis Investigative Site, Manila
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Quezon City
Novartis Investigative Site, Sofia
Novartis Investigative Site, Las Piñas
Novartis Investigative Site, Leuven
Novartis Investigative Site, Malvern East
Novartis Investigative Site, Genk
Novartis Investigative Site, Dasmariñas
Novartis Investigative Site, Lipa City
Novartis Investigative Site, Maroochydore
Novartis Investigative Site, Sevlievo
Novartis Investigative Site, Pleven
Novartis Investigative Site, Ghent
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Duncansville
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Charlotte
Novartis Investigative Site, Columbia
Novartis Investigative Site, Charleston
Novartis Investigative Site, Hildesheim
Novartis Investigative Site, Tamarac
Novartis Investigative Site, Verona
Novartis Investigative Site, Jackson
Novartis Investigative Site, Gommern
Novartis Investigative Site, Zerbst
Novartis Investigative Site, Khon Kaen
Novartis Investigative Site, Ratingen
Novartis Investigative Site, Chiang Mai
Novartis Investigative Site, Cologne
Novartis Investigative Site, Aachen
Novartis Investigative Site, Siena
Novartis Investigative Site, Eagan
Novartis Investigative Site, Prato
Novartis Investigative Site, St Louis
Novartis Investigative Site, Lincoln
Novartis Investigative Site, Oklahoma City
Novartis Investigative Site, Mesquite
Novartis Investigative Site, Dallas
Novartis Investigative Site, Dallas
Novartis Investigative Site, Benbrook
Novartis Investigative Site, Houston
Novartis Investigative Site, League City
Novartis Investigative Site, Ashkelon
Novartis Investigative Site, Mesa
Novartis Investigative Site, Paradise Valley
Novartis Investigative Site, Nuremberg
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Upland
Novartis Investigative Site, Catania
Novartis Investigative Site, Seattle
Novartis Investigative Site, Moscow
Novartis Investigative Site, Singapore
Novartis Investigative Site, Yaroslavl
Novartis Investigative Site, Singapore
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Singapore
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Yekaterinburg
Novartis Investigative Site, Kemerovo
Novartis Investigative Site, Haifa
Novartis Investigative Site, Ramat Gan
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Anniston
Novartis Investigative Site, Freehold
Novartis Investigative Site, CABA
Novartis Investigative Site, Rosario
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site, CABA
Novartis Investigative Site, Córdoba
Novartis Investigative Site, Córdoba
Novartis Investigative Site, Porto Alegre
Novartis Investigative Site, São Paulo
Novartis Investigative Site, São Paulo
Novartis Investigative Site, St. John's
Novartis Investigative Site, St. John's
Novartis Investigative Site, Newmarket
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Trois-Rivières
Novartis Investigative Site, Bruntál
Novartis Investigative Site, Uherské Hradiště
Novartis Investigative Site, Zlín
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Bialystok
Novartis Investigative Site, Warsaw
Novartis Investigative Site, Lučenec
Novartis Investigative Site, Leytonstone
Novartis Investigative Site, Cannock
Novartis Investigative Site, Bradford
Novartis Investigative Site, Glasgow
Novartis Investigative Site, London
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY